BMS picks up Novo Nordisk's unwanted anti-inflammatory program
This article was originally published in Scrip
Executive Summary
Novo Nordisk, no longer interested in the autoimmune space, is making moves to focus almost entirely on its strength in diabetes by divesting assets to Bristol-Myers Squibb. The Danish pharma found a home for its early autoimmune development program with the US pharma.